Abstract
B-cell chronic lymphocytic leukaemia (B-CLL) is a heterogenous disease with a highly variable clinical course and analysis of zeta-associated protein 70 (ZAP-70) and CD38 expression on B-CLL cells allowed for identification of patients with good (ZAP-70−CD38−) and poor (ZAP-70+CD38+) prognosis. DNA microarray technology was employed to compare eight ZAP-70+CD38+ with eight ZAP-70−CD38− B-CLL cases. The expression of 358 genes differed significantly between the two subgroups, including genes involved in B-cell receptor signaling, angiogenesis and lymphomagenesis. Three of these genes, that is, immune receptor translocation-associated protein 4 (IRTA4)/Fc receptor homologue 2 (FcRH2), angiopoietin 2 (ANGPT2) and Pim2 were selected for further validating studies in a cohort of 94 B-CLL patients. IRTA4/FcRH2 expression as detected by flow cytometry was significantly lower in the poor prognosis subgroup as compared to ZAP-70−CD38− B-CLL cells. In healthy individuals, IRTA4/FcRH2 protein expression was associated with a CD19+CD27+ memory cell phenotype. ANGPT2 plasma concentrations were twofold higher in the poor prognosis subgroup (P<0.05). Pim2 was significantly overexpressed in poor prognosis cases and Binet stage C. Disease progression may be related to proangiogenic processes and strong Pim2 expression.
Similar content being viewed by others
References
Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815.
Keating MJ . Chronic lymphocytic leukemia. Semin Oncol 1999; 26 (Suppl 14): 107–114.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.
Shanafelt TD, Geyer SM, Kay NE . Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202–1210.
Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625–1638.
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.
Vasconcelos Y, De Vos J, Vallat L, Reme T, Lalanne AI, Wanherdrick K et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. Leukemia 2005; 19: 2002–2005.
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614.
Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.
Dürig J, Nückel H, Cremer M, Führer A, Halfmeyer K, Fandrey J et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426–2434.
Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750–758.
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.
Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633–2639.
Dürig J, Naschar M, Schmücker U, Renzing-Kohler K, Hölter T, Hüttmann A et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16: 30–35.
Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK . Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455–2457.
Deaglio S, Capobianco A, Bergui L, Dürig J, Morabito F, Dührsen U et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146–2155.
Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005; 105: 3042–3050.
Dürig J, Nückel H, Hüttmann A, Kruse E, Hölter T, Halfmeyer K et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 2003; 101: 2748–2755.
Tusher VG, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116–5121.
Nückel H, Hüttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L et al. LPL expression is a novel prognostic factor in B-CLL. Leukemia Lymphoma 2006; 47: 1053–1061.
Beissbarth T, Speed TP . GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004; 20: 1464–1465.
Guselnikov SV, Ershova SA, Mechetina LV, Najakshin AM, Volkova OY, Alabyev BY et al. A family of highly diverse human and mouse genes structurally links leukocyte FcR, gp42 and PECAM-1. Immunogenetics 2002; 54: 87–95.
Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD . FcRH1: an activation coreceptor on human B cells. Blood 2005; 105: 1121–1126.
Xu MJ, Zhao R, Zhao ZJ . Molecular cloning and characterization of SPAP1, an inhibitory receptor. Biochem Biophys Res Commun 2001; 280: 768–775.
Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB . The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17: 1841–1854.
Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 2004; 64: 8341–8348.
Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB . Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105: 4477–4483.
Allen JD, Verhoeven E, Domen J, van d V, Berns A . Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997; 15: 1133–1141.
Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leukemia Lymphoma 2004; 45: 951–955.
Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164–3173.
Del GI, Morilla A, Osuji N, Matutes E, Morilla R, Burford A et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005; 104: 2124–2132.
Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106: 650–657.
van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006; 91: 56–63.
Porakishvili N, Kulikova N, Jewell AP, Youinou PY, Yong K, Nathwani A et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005; 131: 313–319.
Davis RS, Wang YH, Kubagawa H, Cooper MD . Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 2001; 98: 9772–9777.
Ehrhardt GR, Davis RS, Hsu JT, Leu CM, Ehrhardt A, Cooper MD . The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci USA 2003; 100: 13489–13494.
Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R . IRTAs: a new family of immunoglobulin like receptors differentially expressed in B cells. Blood 2002; 99: 2662–2669.
Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911–919.
Kay NE . The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leukemia Res 2004; 28: 221–222.
Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE . VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005; 19: 513–523.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–1998.
Lobov IB, Brooks PC, Lang RA . Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99: 11205–11210.
Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777–785.
Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005; 23: 1109–1117.
Acknowledgements
We thank Anja Führer and Ute Schmücker for excellent technical assistance and Brigitte Fischer for help with compiling patient data. This work is dedicated to Professor G Brittinger on the occasion of his 75th birthday. This work was supported by a ‘Deutsche Krebshilfe’ grant provided to JD and AC.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Rights and permissions
About this article
Cite this article
Hüttmann, A., Klein-Hitpass, L., Thomale, J. et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 20, 1774–1782 (2006). https://doi.org/10.1038/sj.leu.2404363
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404363
- Springer Nature Limited
Keywords
This article is cited by
-
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
Nature Communications (2022)
-
DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity
Scientific Reports (2021)
-
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
Leukemia (2016)
-
The role of PIM1/PIM2 kinases in tumors of the male reproductive system
Scientific Reports (2016)
-
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype
Cancer Immunology, Immunotherapy (2013)